Quarterly report [Sections 13 or 15(d)]

Acquisitions - Generation Bio Acquisition (Details)

v3.26.1
Acquisitions - Generation Bio Acquisition (Details)
 1 Months Ended
Feb. 09, 2026
USD ($)
Right
$ / shares
shares
Dec. 15, 2025
Apr. 30, 2023
USD ($)
Generation Bio Co      
Asset Acquisition      
Asset acquisition, share price (in dollars per share) | $ / shares $ 4.2913    
Number of non-transferable contractual CVR per share | Right 1    
Threshold period for entitlement of net proceeds   10 years  
Percentage share of net proceeds entitled in year one through two 70.00%    
Percentage share of net proceeds entitled in year three through four 60.00%    
Percentage share of net proceeds entitled in year five through six 50.00%    
Percentage share of net proceeds entitled in year seven through ten 30.00%    
Percentage share of net proceeds entitled related to collaboration and license agreement in year one through three 90.00%    
Percentage share of net proceeds entitled related to collaboration and license agreement in year four through five 80.00%    
Percentage share of net proceeds entitled related to collaboration and license agreement in year six through seven 70.00%    
Percentage share of net proceeds entitled related to collaboration and license agreement in year eight through ten 50.00%    
Lease security deposit $ 2,100,000    
Contingent consideration in asset acquisition $ 0    
Common stock tendered | shares 6,753,846    
Payment for in money options $ 25,000    
Shares issued related to in money options | shares 39,860    
Estimated additional contingent consideration $ 2,500,000    
Termination fee for lease $ 22,400,000    
Generation Bio Co      
Asset Acquisition      
Upfront payment received     $ 40,000,000
Prepaid research funding received     7,500,000
Milestone receivable     $ 1,800,000,000